SanoSwiss - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,508,244 | 7,436,876 | 8,363,677 | 7,896,496 | 5,827,152 | 4,213,900 | 4,627,220 | 4,421,932 |
| Profit before tax | 5,017 | 2,855 | -715,680 | -495,074 | 23,640 | 93,426 | 11,769 | 11,641 |
| Net profit | 2,967 | 862 | -715,680 | -495,074 | 15,701 | 86,145 | 10,606 | 9,443 |
| Equity | 111,376 | 112,239 | -603,441 | -1,098,516 | -1,082,815 | -996,670 | -986,064 | -1,291,381 |
| Liabilities | 1,675,533 | 5,219,204 | 5,172,668 | 6,054,795 | 3,747,132 | 3,442,707 | 3,353,919 | 3,266,701 |
| Non-current assets | 104,798 | 106,535 | 74,662 | 94,025 | 142,096 | 137,366 | 140,362 | 108,323 |
| Current assets | 1,681,742 | 5,165,563 | 4,644,919 | 4,900,952 | 2,448,728 | 2,280,022 | 2,205,275 | 1,838,536 |
| Total assets | 1,786,540 | 5,272,098 | 4,719,581 | 4,994,977 | 2,590,824 | 2,417,388 | 2,345,637 | 1,946,859 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 95,095 | 161,501 | 147,125 |
| Social insurance contributions | - | - | - | - | - | 131,509 | 130,881 | 132,060 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +85.3% | +112.0% | +12.5% | -5.6% | -26.2% | -27.7% | +9.8% | -4.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.2% | 0.0% | -15.2% | -9.9% | 0.6% | 3.6% | 0.5% | 0.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 2.7% | 0.8% | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.1% | 0.0% | -8.6% | -6.3% | 0.3% | 2.0% | 0.2% | 0.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 0.1% | 0.0% | -8.6% | -6.3% | 0.4% | 2.2% | 0.3% | 0.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 15.0 | 46.5 | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 526,234 | 686,483 | 692,168 | 607,423 | 411,327 | 300,993 | 340,655 | 340,149 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SanoSwiss - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-16 | 2026-08-16 | 10.16 |
| 2026-07-23 | 2026-08-14 | 10.16 |
| 2026-05-17 | 2026-05-17 | 12543.79 |
| 2026-03-15 | 2026-03-15 | 5.92 |
| 2026-02-18 | 2026-03-11 | 5.92 |
| 2026-01-21 | 2026-02-12 | 5.92 |
| 2025-10-27 | 2025-11-12 | 3.57 |
| 2025-10-23 | 2025-10-26 | 2.95 |
| 2025-10-16 | 2025-10-16 | 11396.43 |
| 2025-09-16 | 2025-10-15 | 2.90 |
| 2025-09-07 | 2025-09-10 | 2.90 |
| 2025-08-31 | 2025-09-03 | 2.90 |
| 2025-08-19 | 2025-08-29 | 2.90 |
| 2025-07-24 | 2025-08-10 | 2.90 |
| 2025-06-11 | 2025-06-15 | 43.34 |
| 2025-02-18 | 2025-03-13 | 7.95 |
| 2025-01-22 | 2025-02-10 | 7.95 |
| 2024-10-29 | 2024-11-17 | 0.52 |
| 2024-10-24 | 2024-10-27 | 0.52 |
| 2024-08-19 | 2024-09-12 | 3.13 |
| 2024-07-26 | 2024-08-15 | 3.13 |
| 2024-07-24 | 2024-07-25 | 166.79 |
| 2024-07-16 | 2024-07-23 | 163.66 |
| 2024-05-03 | 2024-05-15 | 3.03 |
| 2024-04-23 | 2024-05-01 | 3.03 |
| 2023-10-27 | 2023-11-13 | 4.20 |
| 2023-10-25 | 2023-10-25 | 4.20 |
| 2023-09-18 | 2023-09-28 | 1033.44 |
| 2023-05-02 | 2023-05-10 | 0.45 |
| 2023-04-25 | 2023-04-28 | 0.45 |
| 2023-01-17 | 2023-01-18 | 503.21 |
| 2022-10-28 | 2022-11-14 | 3.18 |
| 2021-11-16 | 2021-11-17 | 206.79 |
SanoSwiss - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-02 | 2026-07-07 | 2907.25 |
| 2026-06-01 | 2026-06-05 | 0.85 |
| 2026-05-20 | 2026-05-20 | 78.63 |
| 2026-05-15 | 2026-05-18 | 11565.28 |
| 2026-03-17 | 2026-03-17 | 4134.5 |
| 2026-03-02 | 2026-03-16 | 0.95 |
| 2026-02-18 | 2026-02-21 | 82.07 |
| 2026-01-23 | 2026-01-27 | 64.33 |
| 2025-12-18 | 2025-12-18 | 75.59 |
| 2025-12-17 | 2025-12-17 | 75.51 |
| 2025-11-18 | 2025-11-20 | 88.88 |
| 2025-11-15 | 2025-11-17 | 10323.62 |
| 2025-10-22 | 2025-11-14 | 0.36 |
| 2025-10-21 | 2025-10-21 | 247.52 |
| 2025-10-18 | 2025-10-20 | 247.22 |
| 2025-09-28 | 2025-10-17 | 1.89 |
| 2025-09-25 | 2025-09-27 | 0.68 |
| 2025-09-22 | 2025-09-24 | 49.97 |
| 2025-09-20 | 2025-09-21 | 49.63 |
| 2025-09-19 | 2025-09-19 | 723.63 |
| 2025-08-21 | 2025-08-22 | 9.18 |
| 2025-07-16 | 2025-07-20 | 8519.25 |
| 2025-06-18 | 2025-06-19 | 86.78 |
| 2025-06-17 | 2025-06-17 | 9825.15 |
| 2025-04-27 | 2025-05-20 | 0.06 |
| 2025-04-23 | 2025-04-26 | 63.11 |
| 2025-04-02 | 2025-04-22 | 0.06 |
| 2025-03-20 | 2025-03-26 | 52.44 |
| 2025-03-02 | 2025-03-03 | 2004.85 |
| 2025-02-28 | 2025-03-01 | 2003.23 |
| 2024-12-17 | 2024-12-17 | 8290.18 |
| 2024-11-20 | 2024-11-23 | 86.24 |
| 2024-10-16 | 2024-10-16 | 9609.86 |
| 2024-10-15 | 2024-10-15 | 13309.37 |
| 2024-10-04 | 2024-10-09 | 5868.66 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SanoSwiss, UAB (code 302332043) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €4.42M and net profit of €9.4K, corresponding to a very thin profit margin of 0.2%. Revenue declined by 4.4% year on year from €4.63M in 2024, after rising from €4.21M in 2023, so the three-year pattern shows growth in 2024 followed by a moderate slowdown in 2025. Profitability weakened sharply from €86.1K in 2023 to €10.6K in 2024 and remained low in 2025. The balance sheet remained leveraged, with liabilities of €3.27M against total assets of €1.95M and negative equity of €1.29M at year-end 2025. Total assets fell from €2.42M in 2023 and €2.35M in 2024, mainly driven by a reduction in short-term assets. Asset turnover was 2.27x, ROA 0.5%, and revenue per employee €340.1K, indicating solid sales intensity but limited bottom-line conversion in 2025.